Free PTCB Supply Chain Exam Flashcards

FDA oversees the safety, efficacy, and security of drugs nationwide - approving products, registering manufacturers and repackagers, and enforcing DSCSA track-and-trace rules. State Boards of Pharmacy, not FDA, license the individual pharmacies and technicians who handle those drugs.

Manufacturers, repackagers, and relabelers must register their establishment with FDA within 5 days of starting operations, then renew every October 1-December 31. FDA's Drug Establishments Current Registration Site (DECRS) is the public, daily-updated list of who is currently registered.

Both wholesale distributors and 3PLs must report certain licensure/facility information to FDA annually - each state license and number, and the name, address, and trade names of each facility. But only wholesale distributors, not 3PLs, must also report any significant state or federal disciplinary action taken against them (21 U.S.C. 353(e)(2)(A)(ii) vs. 360eee-3(b)).

Red flags include grey-market pricing (sold outside the manufacturer's authorized channels), misbranded or mismatched labeling, and poor product integrity (damaged packaging, wrong color/texture, or missing security features) - any of these should trigger a suspect-product investigation before the product is dispensed or further distributed.

DEA registration is location-specific, not company-wide: 21 CFR 1301.12(a) requires a separate registration for each principal place of business or practice where controlled substances are manufactured, distributed, or dispensed. A chain with 3 pharmacy locations needs 3 separate DEA registrations.

The paper order form used to purchase or transfer Schedule I or II controlled substances (21 CFR Part 1305). Only the DEA registrant, or someone holding a valid power of attorney from the registrant, may sign it.

DEA's electronic alternative to Form 222: digital certificates are issued and used under 21 CFR Part 1311 Subpart B, and the electronic orders themselves (for Schedule I/II) are governed by 21 CFR Part 1305 Subpart C. DEA describes CSOS as supporting secure electronic ordering across Schedules I-V - broader than the paper Form 222, which covers only Schedule I/II.

A registrant must notify its local DEA Field Division Office in writing within 1 business day of discovering a theft or significant loss, then file Form DEA-106 electronically within 45 days. Paper Form 106 submissions were discontinued after July 24, 2023.

Every wholesale distributor must hold a state license - or, where a state has no licensure program, a federal (FDA) license instead (21 U.S.C. 353(e)(1)). State Boards of Pharmacy also license the pharmacies, technicians, and, in many states, 3PLs operating in-state - a layer of oversight alongside, not instead of, FDA's and DEA's federal authority.

Under DSCSA Title II, a 'product' is a prescription drug in a finished dosage form ready for administration (e.g., a tablet or capsule). Exclusions include blood/blood components, radioactive or NRC-regulated biologics, imaging drugs, medical gases, and drugs compounded under 503A or 503B.

A DSCSA 'transaction' is a change of ownership between persons - but the law excludes several transfers from that definition, including intracompany distribution, emergency public-health distribution, and minimal-quantity transfers from a retail pharmacy to a practitioner for office use.

DSCSA requires a product identifier (the NDC plus a serial number, lot number and expiration date) in human-readable text and a machine-readable barcode: a 2D data matrix on each package, and a linear or 2D barcode on each homogeneous case (FD&C 581(14), 582(a)(9)). This package-level serialization is what makes electronic tracing back to the manufacturer possible.

One of the three 'T3' documents (industry shorthand that PTCB's outline uses; TH itself is defined in FD&C 581(25)): a cumulative record, in paper or electronic form, of every prior change of ownership of a product going back to the manufacturer. Under section 582(k)(1), the legal requirement to provide and receive TH actually sunset on November 27, 2023, once package-level serialization took over that tracing role.

The second T3 document: the product's name, strength, and dosage form, NDC number, container size and count, lot number, and transaction/shipment dates. TI is data about the product and sale, not a legal statement.

The third T3 document: the seller's formal declaration that it is authorized, received the product from an authorized source, did not knowingly ship a suspect or illegitimate product, and did not alter the transaction history. TS is the attestation, not the data.

DSCSA requires transaction information and transaction statements to be exchanged in a secure, interoperable, electronic format. PTCB's outline gives EDI as an example transmission method; FDA specifically recommends the GS1 EPCIS (Electronic Product Code Information Services) standard for it today. Either way, that rules out fax or an unsecured spreadsheet once EDDS enforcement applies to a given trading partner.

Under section 582 ((d)(1)(A) for dispensers; parallel (c) and (e) provisions for wholesalers and repackagers), a trading partner shall not accept ownership of a product unless the prior owner provides transaction information and a transaction statement (TI + TS) at or before the transaction. The data must be kept at least 6 years and produced to FDA or officials on request.

A 'suspect' product is one there's reason to believe may be counterfeit, diverted, stolen, intentionally adulterated to cause serious harm, or involved in a fraudulent transaction - it triggers an investigation. Once confirmed illegitimate, the holder must notify its immediate trading partners and notify FDA within 24 hours of that determination.

The law's legal effective date was November 27, 2023 (section 582(g)(1)) - not 2024. FDA delayed real enforcement first to November 27, 2024 (a stabilization period), then granted eligible trading partners phased exemptions into 2025 by type: manufacturers/repackagers by 5/27/25, wholesalers by 8/27/25, larger dispensers (26+ pharmacist/technician FTEs) by 11/27/25. Small dispensers (25 or fewer FTEs) are now exempted until November 27, 2027, per FDA's August 2026 letter.

Pharmacies must maintain organized records for invoices, recalls, wastage, general inventory, and hazardous-drug handling. As a baseline: DEA-required controlled-substance records must be kept at least 2 years, DSCSA transaction data at least 6 years - and some states require longer retention than either federal floor.

DEA requires an initial inventory when a registrant starts handling controlled substances, then a complete new count at least every 2 years (21 CFR 1304.11(c)). Schedule I/II must always be counted exactly; Schedule III-V may be estimated unless an opened container holds more than 1,000 tablets or capsules, which then requires an exact count (21 CFR 1304.11(e)(6)).

A DEA/state-licensed entity that takes back a pharmacy's expired, damaged, or recalled drugs - including controlled substances - for proper destruction or manufacturer credit. The originating pharmacy still records the transfer (21 CFR 1304.22(c)) and keeps that record for 2 years (21 CFR 1304.04); for Schedule II drugs, the reverse distributor issues a DEA Form 222 to receive them.

An informal, low-tech reorder tool: staff jot down items running low as they notice them during the day. It's a manual supplement to formal reordering systems - not a substitute for barcode-driven perpetual tracking or automated par-level ordering.

The target stock quantity a pharmacy wants on hand for an item. Par level is often the 'max' in a broader min-max ordering system: stock is watched until it drops to a minimum reorder point, then an order is placed to bring it back up to par. Setting par too low risks stockouts; too high ties up cash and shelf space.

Orders are timed to arrive right before the drug is needed, keeping on-hand stock - and carrying cost - low. The trade-off: JIT leaves little buffer if a shipment is delayed or demand suddenly spikes.

Stock counts update automatically with every sale, receipt, or transfer, so the system always reflects a real-time on-hand quantity. This differs from a periodic system, which only knows the count as of the last physical inventory.

A formulary drug is on the facility's or plan's pre-approved stocking/coverage list and can be dispensed routinely. A non-formulary drug isn't - it typically needs a prior authorization, a special order, or a therapeutic-substitution review first.

Seasonal forecasting anticipates predictable demand swings, like stocking more flu vaccine and antivirals each fall. Emergency forecasting reacts to unpredictable surges, like a natural disaster or disease outbreak, where standard reorder points don't apply.

Automated dispensing cabinets (ADCs), storage carousels, barcode scanning at receiving, and systems that feed a perpetual count are common automation examples. Each reduces manual counting errors and speeds up reordering compared with a fully manual, paper-based process.

Turnover (turns) = Cost of Goods Sold divided by Average Inventory Value; days' supply = 365 divided by turns. Turns measures how many times stock is sold and replaced in a year; days' supply converts that into how long current stock would last at the current usage rate. Low turns with high days'-supply usually flags overstocking.

When a drug is in short supply, pharmacies may substitute a therapeutic alternative, tighten par levels, or ration remaining stock - and should watch for secondary sellers charging steep, shortage-driven price increases rather than paying an inflated price to restock quickly.

An individual contract is negotiated directly between one pharmacy/health system and a supplier. A Group Purchasing Organization (GPO) and smaller buying groups are both formal membership organizations that pool members' purchasing volume for better collective pricing. Consignment stock, by contrast, stays owned by the supplier until it's used or sold.

A core 340B compliance rule: certain hospital covered entities may not buy their covered outpatient drugs through a Group Purchasing Organization (GPO). (A related rule bars a manufacturer from having to give both a 340B discount and a Medicaid rebate on the same dispensed unit.)

CDC's VFC Operations Guide (supplemented by the Vaccine Storage and Handling Toolkit) requires publicly-purchased vaccine stock (like VFC) to be kept clearly separated - physically or virtually - from privately purchased stock, with limited exceptions such as replacement ordering and the handful of 'universal purchase' states that buy vaccine for all children regardless of insurance.

When a commercial product is on shortage or unavailable, a pharmacy may source a patient-specific compounded version from a licensed 503A compounding pharmacy instead - a different supply channel than ordering the same drug from a wholesaler.

Terms for where a specialty or provider-administered drug is dispensed from before reaching the patient: white bagging (an outside specialty pharmacy ships it to the provider), brown bagging (the patient carries it to the provider), and clear bagging (the health system's own internal specialty pharmacy dispenses and delivers it to the system's own clinic or infusion site) - each shifts chain-of-custody and storage responsibility differently.

Rx manufacturers bring prescription products to market through an FDA New Drug Application (NDA) or Abbreviated NDA (generic). OTC manufacturers market nonprescription products, typically under an FDA OTC monograph or their own approved application - a different regulatory pathway and labeling standard.

A repackager changes a drug's container or packaging without altering the drug itself; a relabeler changes only the labeling. Both are manufacturing operations under 21 CFR Part 207 and must register with FDA and list their products, just like a manufacturer.

A full-line distributor that buys directly from manufacturers and stocks a broad catalog of products across many manufacturers, serving as a pharmacy's main day-to-day source for most drugs.

Secondary wholesale distributors are typically smaller, independent operators that supplement a primary wholesaler - often filling gaps or sourcing hard-to-find items. Specialty distributors focus on high-cost, complex-handling drugs (biologics, injectables, oncology) regardless of company size - many are actually specialty divisions of the same 'Big Three' wholesalers rather than small independents.

A distributor that handles only nonprescription products. Because DSCSA's 'product' definition covers prescription drugs in finished dosage form, an OTC-only distributor generally falls outside DSCSA's track-and-trace and T3 documentation requirements.

Per NABP's Drug Distributor Accreditation criteria, a 'virtual' wholesale distributor still meets the legal definition of a wholesale distributor and must be licensed and trade only with authorized trading partners - it simply never physically possesses the drug, relying on an accredited distributor or 3PL for the actual physical handling and shipping.

Holds the FDA-approved application (e.g., the NDA) and sells the product under its own name, but contracts the actual physical production out to a separate contract manufacturer. That contract manufacturer still must register its own establishment with FDA.

Provides or coordinates warehousing and other logistics for a product in interstate commerce on behalf of a manufacturer, wholesaler, or dispenser - without ever taking ownership of the product or responsibility for its sale.

Manufacturers, repackagers, wholesale distributors, and dispensers - the four trading-partner categories directly subject to section 582 product tracing. Third-party logistics providers (3PLs) are trading partners too (section 581(23)(B)), but FDA's Aug 2026 exemption letter notes 3PLs are not subject to section 582's product-tracing requirements.

An FDA-registered facility that can compound sterile drugs in bulk, cGMP-compliant batches - without a patient-specific prescription - for hospitals, clinics, or other facilities to keep in stock for office use.

A 503B facility can't compound a drug that is 'essentially a copy' of an FDA-approved drug unless that drug is on FDA's drug shortage list (503B(a)(5), (d)(2)). And only the outsourcing facility itself may sell or transfer what it compounds: a hospital that buys it may administer it or dispense it on a prescription, but not resell it (503B(a)(8)). Labels must say 'Not for resale.'

Drugs entering the U.S. supply chain from outside authorized manufacturer/importer channels may not carry valid DSCSA transaction data, making them harder to verify and a common vector for counterfeit or diverted product. FDA import controls specifically target this risk at the border.

A pharmacy can distribute controlled substances to another pharmacy without registering as a distributor, but for Schedule II a DEA Form 222 (or electronic equivalent) is required, both pharmacies must record the transfer, and the total distributed this way can't exceed 5% of the pharmacy's total annual controlled-substance dosage units (21 CFR 1307.11(a)(1)).

The physical drug - moving a patient's prescription record to another pharmacy is a completely different process. Legally, a DSCSA 'transaction' is a change of ownership, not just physical movement, and a pharmacy-to-pharmacy sale to fill one specific, identified patient's prescription means the selling pharmacy need not pass TI/TS (section 582(d)(1)(A)(ii)); transfers made just to restock inventory are not exempt.